Matches in Wikidata for { <http://www.wikidata.org/entity/Q63315663> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- Q63315663 description "assaig clínic" @default.
- Q63315663 description "clinical trial" @default.
- Q63315663 description "clinical trial" @default.
- Q63315663 description "clinical trial" @default.
- Q63315663 description "clinical trial" @default.
- Q63315663 description "ensaio clínico" @default.
- Q63315663 description "ensayo clínico" @default.
- Q63315663 description "ensayu clínicu" @default.
- Q63315663 description "essai clinique" @default.
- Q63315663 description "klinisch onderzoek" @default.
- Q63315663 description "клінічне випробування" @default.
- Q63315663 description "临床试验" @default.
- Q63315663 name "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications" @default.
- Q63315663 type Item @default.
- Q63315663 label "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications" @default.
- Q63315663 prefLabel "A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler (Puffer) in Adolescents and Adults Who Have Asthma That is Not Controlled by High Dose Inhaled Corticosteroid Asthma Medications" @default.
- Q63315663 P1050 Q63315663-6AB95E9A-8D76-4A8F-9E67-35B189F6A38D @default.
- Q63315663 P1132 Q63315663-792D6607-7445-447D-8DA1-688E6872DA4E @default.
- Q63315663 P1476 Q63315663-4C6C3FAB-6C0F-4CF0-B484-BA4F9330AE89 @default.
- Q63315663 P17 Q63315663-0DF05925-DA95-46B2-8096-84EA08965C30 @default.
- Q63315663 P17 Q63315663-134B307E-B655-4B76-BE23-D8BBA9C8B124 @default.
- Q63315663 P17 Q63315663-1B4436C0-8A07-4A0B-8019-39D49C806DBE @default.
- Q63315663 P17 Q63315663-225C0C66-23E8-4ABB-AB70-FB871DA5A4EE @default.
- Q63315663 P17 Q63315663-3C2E100F-2895-474C-A255-2D893686BDA3 @default.
- Q63315663 P17 Q63315663-42F15ED1-4AFF-4482-BE20-A339B449E139 @default.
- Q63315663 P17 Q63315663-4F18B6CE-01E9-4AC6-8885-71681029CA12 @default.
- Q63315663 P17 Q63315663-5C7069DC-B746-480B-83A8-4C760AD064C1 @default.
- Q63315663 P17 Q63315663-686C7BAA-5396-4B97-9DBB-3AA5139CBBD8 @default.
- Q63315663 P17 Q63315663-77042F9D-8482-430C-AB4A-90A231EA646D @default.
- Q63315663 P17 Q63315663-79EBFD48-629F-4B5F-93DC-A371B6E56283 @default.
- Q63315663 P17 Q63315663-8B9FC0F4-7674-4988-9C47-A3CCE5CECC14 @default.
- Q63315663 P17 Q63315663-8F28CF3A-B9B0-42D3-991B-15BEEF27467B @default.
- Q63315663 P17 Q63315663-9869CF0C-626C-4A6B-ADC6-25DF9F1E17FF @default.
- Q63315663 P17 Q63315663-B77D7E8C-0093-48BD-A5CB-72ED66ECCF5A @default.
- Q63315663 P17 Q63315663-E2D823B6-C966-4BC1-86A7-E74CC610907D @default.
- Q63315663 P17 Q63315663-F939678C-FDC1-4BBA-84BC-3C186F326030 @default.
- Q63315663 P17 Q63315663-FA506FE8-D441-4E5C-A92F-65A5173BDA8B @default.
- Q63315663 P2899 Q63315663-342209BF-210F-41BC-BCDC-1B130796C747 @default.
- Q63315663 P3098 Q63315663-DC50996B-4373-4DD1-B4BC-F25C55B52CE0 @default.
- Q63315663 P31 Q63315663-ECE3EFD3-48D8-4803-84E8-4CFD6FF3DF7B @default.
- Q63315663 P4844 Q63315663-20E26429-23ED-4475-A31B-5C24858E201A @default.
- Q63315663 P4844 Q63315663-2425C2B2-7ED4-4029-A9E7-1DAF7A769633 @default.
- Q63315663 P4844 Q63315663-765AD30C-AEE9-49E7-9BA8-DFF1E22942F4 @default.
- Q63315663 P580 Q63315663-D31680A1-2CA7-4272-A4D9-480260691C94 @default.
- Q63315663 P582 Q63315663-4933CB32-076C-4E2F-B738-2573373D4F96 @default.
- Q63315663 P6099 Q63315663-7FFF5CEE-FA86-4DB8-AAAC-43FB03A35556 @default.
- Q63315663 P8005 Q63315663-74B13E12-A6E2-4A7B-B41F-AAA4B54D10E8 @default.
- Q63315663 P8363 Q63315663-0284A043-7182-4D1E-AEE9-86B6333EE249 @default.
- Q63315663 P1050 Q35869 @default.
- Q63315663 P1132 "+889" @default.
- Q63315663 P1476 "A 12-Week Dose-ranging Study to Evaluate the Efficacy and Safety of Fp Spiromax® (Fluticasone Propionate Inhalation Powder) Administered Twice Daily Compared With Placebo in Adolescent and Adult Subjects With Severe Persistent Asthma Uncontrolled on High Dose Inhaled Corticosteroid Therapy" @default.
- Q63315663 P17 Q145 @default.
- Q63315663 P17 Q16 @default.
- Q63315663 P17 Q183 @default.
- Q63315663 P17 Q212 @default.
- Q63315663 P17 Q218 @default.
- Q63315663 P17 Q219 @default.
- Q63315663 P17 Q224 @default.
- Q63315663 P17 Q258 @default.
- Q63315663 P17 Q27 @default.
- Q63315663 P17 Q28 @default.
- Q63315663 P17 Q29 @default.
- Q63315663 P17 Q30 @default.
- Q63315663 P17 Q36 @default.
- Q63315663 P17 Q403 @default.
- Q63315663 P17 Q408 @default.
- Q63315663 P17 Q41 @default.
- Q63315663 P17 Q664 @default.
- Q63315663 P17 Q801 @default.
- Q63315663 P2899 "+12" @default.
- Q63315663 P3098 "NCT01576718" @default.
- Q63315663 P31 Q30612 @default.
- Q63315663 P4844 Q1002165 @default.
- Q63315663 P4844 Q48566653 @default.
- Q63315663 P4844 Q50430229 @default.
- Q63315663 P580 "2012-04-01T00:00:00Z" @default.
- Q63315663 P582 "2013-07-01T00:00:00Z" @default.
- Q63315663 P6099 Q42824440 @default.
- Q63315663 P8005 Q76651189 @default.
- Q63315663 P8363 Q78089383 @default.